We are pleased to announce Cardio-Oncology has been accepted for indexing in the Emerging Sources Citation Index. All articles published in Cardio-Oncology are also archived and searchable through PubMed Central. The journal has passed the rigorous evaluation required for a journal to be included in these indexes.
Aims and scope
The editorial mission of Cardio-Oncology is to advance the science and practice of this emerging field to find a balance between oncologic efficacy and reducing adverse cardiovascular effects through timely publication and dissemination of peer-reviewed research. As an open access, online journal Cardio-Oncology provides a high visibility platform for the publication of original research and expert reviews on the cardiovascular effects of cancer treatment. Read more here.
Springer Nature Oncology Portfolio
Discover the range of academic oncology titles at Springer Nature here.
About the society
Cardio-Oncology is the official journal of the International Cardio-Oncology Society (ICOS). The society brings together cardio-oncologists from around the world with the aim of reducing cardiovascular disease in cancer patients and thereby saving patients' lives. For more information about this important work, please visit the ICOS website.
Members of ICOS currently receive a 25% discount on submissions. The discount should be requested using the ICOS discount code during the submission process. ICOS members unsure of the code for society members, should contact the Journal Development Manager.
Cardio-Oncology now welcomes well-described reports of cases that include the following:
- Unreported or unusual side effects or adverse interactions involving medications.
- Unexpected or unusual presentations of a disease.
- New associations or variations in disease processes.
- Presentations, diagnoses and/or management of new and emerging diseases.
- An unexpected association between diseases or symptoms.
- An unexpected event in the course of observing or treating a patient.
- Findings that shed new light on the possible pathogenesis of a disease or an adverse effect.
Authors are encouraged to describe how the case report is rare or unusual as well as its educational and/or scientific merits in the covering letter that accompanies the submission of the manuscript.
Announcing the launch of In Review
Cardio-Oncology, in partnership with Research Square, is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
About the Editors
Steven Lipshultz, Editor-in-Chief
Steven E. Lipshultz, MD, FAAP, FAHA is the A. Conger Goodyear Professor and Chair of the Department of Pediatrics at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, The State University of New York; the Chief of Service of Pediatrics at Kaleida Health; the Medical Director of Pediatric Services Business Development at John R. Oishei Children’s Hospital; President of UBMD Pediatrics (University at Buffalo Pediatric Associates, Inc.); and a Consultant in Pediatrics and Cardio-Oncology for the Roswell Park Comprehensive Cancer Center.
Joseph Carver, Deputy Editor
Joseph Carver is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center.
Giorgio Minotti, Deputy Editor
Giorgio Minotti is Professor of Pharmacology, Head of Drug Sciences and Clinical Pharmacology, Chief of Clinical Trial Center, at the University Campus Bio-Medico of Rome. His research interests focus on pharmacokinetics, pharmacodynamics, and clinical correlates of anticancer drugs cardiovascular toxicity.
Cardio-Oncology is affiliated with the International Cardio-Oncology Society (ICOS).
- Editorial Board
- Instructions for Editors
- Sign up for article alerts and news from this journal
Annual Journal Metrics
37 days to first decision for reviewed manuscripts only
34 days to first decision for all manuscripts
74 days from submission to acceptance
17 days from acceptance to publication
280 Altmetric Mentions
On the blog
16 April 2021
19 February 2021
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).